NASDAQ: REGN Lawsuit Against Directors Pending - Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Long Should Contact the Shareholders Foundation
SAN DIEGO, CA, September 10, 2024 (Newswire.com) - The Shareholders Foundation, Inc. announces that a lawsuit is currently pending by an investor in NASDAQ:REGN shares against certain directors of Regeneron Pharmaceuticals, Inc. Investor in NASDAQ:REGN shares should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554
The Shareholders Foundation, Inc. announces that a lawsuit is currently pending by an investor in NASDAQ:REGN shares against certain directors of Regeneron Pharmaceuticals, Inc.
Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) long-term and continue to hold any of those NASDAQ:REGN shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
In June 2021 an investor in NASDAQ: REGN shares filed a lawsuit against certain directors of Regeneron Pharmaceuticals, Inc. alleging breaches of fiduciary duty. The plaintiff claims that "many of the Individual Defendants, including a majority of the current Board members, collectively sold over $650 million in Regeneron stock (pursuant to the exercise of stock options) during this time" and that the lawsuit "seeks to recover those damages for the benefit of the Company from the true wrongdoers - the officers and directors of Regeneron."
The plaintiff said that the lawsuit arose from the allegedly improper behavior of Regeneron with the allegations originating from another lawsuit against Regeneron from June 2020. Back in June 2020, the United States initiated a lawsuit against Regeneron. The core allegation in that action is that Regeneron allegedly improperly covered Eylea's copay for Medicare beneficiaries through purported charitable donations, which the United States claims violated the federal Anti-Kickback Statute and False Claims Act.
Both cases are currently pending.
Those who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
Contact Information
Michael Daniels
Manager
mail@shareholdersfoundation.com
858-779-1554
SOURCE: Shareholders Foundation, Inc
Source: Shareholders Foundation, Inc.
Related Media
